| Assessment Status | Rapid Review Complete |
| HTA ID | 26035 |
| Drug | Serplulimab |
| Brand | Hetronifly® |
| Indication | Serplulimab (Hetronifly®) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with non-squamous NSCLC with no EGFR, ALK or ROS1 positive mutations and who have locally advanced NSCLC who are not candidates for surgery or radiotherapy, or metastatic NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 10/07/2026 |
| Rapid review completed | 14/08/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that serplulimab not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here